Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic official newsroom · 行業原文收錄 · 來源發佈:Mon Oct 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄:Mon Oct 26 2026 12:07:42 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
IAM1363, now in a Phase 1/1b stud y , was designed using Iambic’s molecular superintelligence platform and brought to clinic al development in approximately two years D ata presented at ESMO 2026 demonstrates IAM1363 was well tolerated with low rates of Grade 3 or higher treatment-related adverse events, serious adverse events , and dose modifications M ore than half of participants dosed at 960 m
以上為帶出處的原文節選,完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。